57_CD 13_CD TANGIBLE_NNP FIXED_NNP ASSETS_NNP Physical_NNP assets_NNS held_VBD for_IN continuing_VBG use_NN in_IN the_DT business_NN ._.
Short_JJ Freehold_NNP leasehold_NN Laboratory_NN and_CC land_NN and_CC land_NN and_CC manufacturing_NN Office_NNP buildings_NNS buildings_NNS equipment_NN equipment_NN Total_NNP Group_NNP mmmmm_NN Cost_NN At_IN 1_CD January_NNP 2003_CD 13.9_CD 7.6_CD 1.7_CD 23.2_CD Additions_NNS 0.6_CD 2.9_CD 1.9_CD 1.0_CD 6.4_CD Disposals_NNS 0.4_CD 0.1_CD 0.5_CD A_DT Exchange_NNP movement_NN 1.6_CD 1.0_CD 0.2_CD 2.8_CD At_IN 31_CD December_NNP 2003_CD 0.6_CD 14.8_CD 8.4_CD 2.5_CD 26.3_CD Depreciation_NN At_IN 1_CD January_NNP 2003_CD 1.6_CD 1.2_CD 0.4_CD 3.2_CD Charge_NNP for_IN year_NN 1.1_CD 1.2_CD 0.6_CD 2.9_CD Disposals_NNS 0.1_CD 0.1_CD A_DT Exchange_NNP movement_NN 0.3_CD 0.3_CD 0.1_CD 0.7_CD At_IN 31_CD December_NNP 2003_CD 2.4_CD 2.0_CD 0.9_CD 5.3_CD Net_JJ book_NN value_NN At_IN 1_CD January_NNP 2003_CD 12.3_CD 6.4_CD 1.3_CD 20.0_CD At_IN 31_CD December_NNP 2003_CD 0.6_CD 12.4_CD 6.4_CD 1.6_CD 21.0_CD Net_JJ book_NN value_NN of_IN assets_NNS held_VBN under_IN finance_NN lease_NN included_VBD above_IN :_: At_IN 1_CD January_NNP 2003_CD 4.6_CD 1.9_CD 6.5_CD At_IN 31_CD December_NNP 2003_CD 4.0_CD 1.7_CD 5.7_CD The_DT Company_NN has_VBZ no_DT tangible_JJ fixed_JJ assets_NNS ._.
14_CD FIXED_VBN ASSET_NN INVESTMENTS_NNS These_DT are_VBP assets_NNS including_VBG shares_NNS that_WDT are_VBP held_VBN as_IN an_DT ongoing_JJ investment_NN ._.
Group_NNP Company_NNP 2003 2002 2003 2002_CD m_FW m_FW m_FW m_FW A_DT Subsidiary_NNP undertakings_NNS 15.0_CD 15.0_CD B_NNP Trade_NNP investments_NNS 0.8_CD 0.3_CD C_NNP Investment_NNP in_IN own_JJ shares_NNS 0.4_CD 0.8_CD 0.4_CD 0.1_CD 1.2_CD 1.1_CD 15.4_CD 15.1_CD A_DT SUBSIDIARY_NN UNDERTAKINGS_NNP Company_NNP name_NN Main_NNP business_NN Country_NN of_IN incorporation_NN Parent_NNP company_NN %_NN owned_VBN Acambis_NNP Research_NNP Limited_NNP R&D_NNP and_CC sales_NNS England_NNP and_CC Wales_NNP Acambis_NNP plc_NN 100_CD %_NN Acambis_NNP Inc._NNP ._.
R&D_NNP ,_, sales_NNS and_CC manufacturing_VBG US_NNP Acambis_NNP plc_NN 100_CD %_NN Berna_NNP Products_NNP Corporation_NNP Sales_NNS ,_, marketing_NN and_CC distribution_NN US_NNP Acambis_NNP Inc._NNP 100_CD %_NN Smallpox_NNP Biosecurity_NNP Limited_NNP Marketing_NNP England_NNP and_CC Wales_NNP Acambis_NNP plc_NN 100_CD %_NN These_DT subsidiaries_NNS are_VBP all_DT consolidated_JJ into_IN the_DT Group_NNP accounts_NNS ._.
THE_DT INFORMATION_NNP IN_IN THIS_NNP BORDER_NNP HAS_VBZ NOT_RB BEEN_JJ AUDITED_JJ A_DT EXCHANGE_NN MOVEMENT_NN FROM_IN 31_CD DECEMBER_NNP 2002_CD TO_TO 31_CD DECEMBER_NNP 2003_CD ,_, THE_DT MONTHLY_NNP CLOSING_NNP US_NNP $_$ EXCHANGE_NN RATE_NN HAS_VBZ VARIED_JJ BETWEEN_IN 1.6095_CD AND_CC 1.7905_CD ._.
THIS_NNP HAS_VBZ GIVEN_NNP RISE_NNP TO_TO AN_DT EXCHANGE_NN RATE_NN MOVEMENT_NN ON_IN THE_DT ASSETS_NNP LOCATED_NNP IN_IN THE_DT US_NNP ,_, WHICH_WDT HAS_VBZ AN_DT IMPACT_NN ON_IN BOTH_DT ASSET_NN COST_NN AND_CC ACCUMULATED_VBN DEPRECIATION_NN ._.
